Role of CCL3/MIP-1alpha and CCL5/RANTES during acute Trypanosoma cruzi infection in rats.
Chagas' disease is caused by Trypanosoma cruzi infection and is characterized by chronic fibrogenic inflammation and heart dysfunction. Chemokines are produced during infection and drive tissue inflammation. In rats, acute infection is characterized by intense myocarditis and regression of inflammation after control of parasitism. We investigated the role of CCL3 and CCL5 during infection by using DNA vaccination encoding for each chemokine separately or simultaneously. MetRANTES treatment was used to evaluate the role of CCR1 and CCR5, the receptors for CCL3 and CCL5. Vaccination with CCL3 or CCL5 increased heart parasitism and decreased local IFN-gamma production, but did not influence intensity of inflammation. Simultaneous treatment with both plasmids or treatment with MetRANTES enhanced cardiac inflammation, fibrosis and parasitism. In conclusion, chemokines CCL3 and CCL5 are relevant, but not essential, for control of T. cruzi infection in rats. On the other hand, combined blockade of these chemokines or their receptors enhanced tissue inflammation and fibrosis, clearly contrasting with available data in murine models of T. cruzi infection. These data reinforce the important role of chemokines during T. cruzi infection but suggest that caution must be taken when expanding the therapeutic modulation of the chemokine system in mice to the human infection.
Roffê
Ester
E
Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. roffeest@niaid.nih.gov
Oliveira
Fabiano
F
Souza
Adriano L S
AL
Pinho
Vanessa
V
Souza
Danielle G
DG
Souza
Patrícia R S
PR
Russo
Remo C
RC
Santiago
Helton C
HC
Romanha
Alvaro J
AJ
Tanowitz
Herbert B
HB
Valenzuela
Jesus G
JG
Teixeira
Mauro M
MM
D000818:Animals; D002598:Chagas Cardiomyopathy / Q000276:immunology* / Q000473:pathology; D054405:Chemokine CCL3 / Q000276:immunology*; D018946:Chemokine CCL5 / Q000276:immunology*; D006321:Heart / Q000469:parasitology; D009206:Myocardium / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D014349:Trypanosoma cruzi / Q000276:immunology* / Q000472:pathogenicity; D019444:Vaccines, DNA / Q000008:administration & dosage
D054405:Chemokine CCL3; D018946:Chemokine CCL5; D019444:Vaccines, DNA
Clin Immunol. 2002 Mar;102(3):302-9
11890717
Am J Trop Med Hyg. 1997 May;56(5):485-9
9180594
J Parasitol. 1988 Jun;74(3):370-4
3132546
Gut. 2005 Aug;54(8):1114-20
16009684
Vaccine. 2006 Jan 16;24(3):374-90
16154670
Microbes Infect. 2009 Feb;11(2):264-73
19100857
J Immunol. 1998 Oct 15;161(8):3870-9
9780152
J Infect Dis. 2006 Jun 1;193(11):1584-8
16652288
J Infect Dis. 2005 Feb 15;191(4):627-36
15655788
Infect Immun. 2006 Jan;74(1):135-43
16368966
Clin Biochem. 1996 Jun;29(3):225-9
8740508
Microbes Infect. 2006 Oct;8(12-13):2745-55
16979363
Infect Immun. 1999 Sep;67(9):4819-26
10456936
Immunol Today. 1998 Dec;19(12):568-74
9864948
Br J Pharmacol. 2000 Dec;131(8):1800-8
11139461
Trends Parasitol. 2003 Nov;19(11):495-501
14580960
J Infect Dis. 2004 Jan 15;189(2):214-20
14722885
Infect Immun. 2004 Aug;72(8):4918-23
15271961
J Clin Invest. 2000 Aug;106(3):361-71
10930439
Front Biosci. 2003 Jan 01;8:e44-54
12456332
Infect Immun. 2006 Jan;74(1):125-34
16368965
Circulation. 2004 Sep 14;110(11):1443-9
15337689
Am J Trop Med Hyg. 1993 May;48(5):637-44
8517482
Blood. 2001 Feb 15;97(4):1144-6
11159551
N Engl J Med. 2006 Feb 9;354(6):610-21
16467548
Am Heart J. 1986 Feb;111(2):307-12
3946173
Circulation. 2000 Dec 12;102(24):3003-8
11113053